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non-pharmacological cost avoidance assessment we determined that apixaban can 
be a cost saving alternative in the long term. Versus SoC (warfarin), apixaban may 
be the only NOAC with consistent benefit on all relevant events. Consistent with 
trial data, lifetime modeling suggested reduction in the mortality.
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Objectives: AF is the most common chronic cardiac arrhythmia worldwide and is 
an important risk factor for morbidity related mainly to an increased risk of cerebro-
vascular events and heart failure. This study examined the prevalence of comor-
bidities among patients receiving treatment for AF in 4 Latin America countries to 
convey a more comprehensive picture of the total disease burden. MethOds: For 
study purposes, co-morbidity was defined as the presence of one or more disorders 
in addition to a primary disease, or the effect of such additional disorders. A 3-step 
process was conducted in order to understand treatment patterns for patients suffer-
ing from AF: 1) health care assessment per country; 2) evaluate patient’s information; 
and 3) data analysis to understand and determine treatment algorithms. Data were 
collected through 59 face-to-face interviews with cardiologists in Argentina, Brazil, 
Chile, and Venezuela. Results: Analysis per country suggested that, in Chile and 
Venezuela, 98% and 94% of patients, respectively, reported at least one co-morbidity. 
In Argentina this pattern was observed in 81% of the patients, whereas in Brazil 
this was 78%. Findings revealed that the main 5 comorbidities associated with AF 
were: 1) Hypertension: LatAm 43%, Argentina 28%, Brazil 45%, Chile 43%, Venezuela 
33%; 2) Dyslipidemia: LatAm 22%, Argentina 11%, Brazil 25%, Chile 21%, Venezuela 
18%; 3) Diabetes: LatAm 13%, Argentina 8%, Brazil 11%, Chile 10%, Venezuela 18%; 
4) Cardiopathies: LatAm 8%, Argentina 4%, Brazil 8%, Chile 8%, Venezuela 9%; 
and 5) Thyroid disease: LatAm 7%, Argentina 4%, Brazil 3%, Chile 12%, Venezuela 
9%. cOnclusiOns: Overall, the analysis suggests that hypertension is the main 
co-morbidity associated with AF, followed by dyslipidemia and diabetes. The health 
burden carried by patients often extends far beyond AF. Physicians should carefully 
consider comorbidities and concomitant medications when managing patients.
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Objectives: Heart failure (HF) ranks high in hospital utilization, cost and quality/
safety consequences. We studied occult HF as secondary diagnosis (2Dx) in a multi-
centric study of the A-HCUPs. MethOds: A multi-centric cross sectional study of 1 
year hospital discharges adapted HCUPs for Argentina. We estimated HF by HCUPs’ 
CCS#108 SL (heart failure) in 2Dx to measure submerged HF; obtained HF in first diag-
nosis (1Dx), and 365 day readmissions (ReH), < 30 day ReH, mortality and case fatality. 
2Dx1= in first secondary Dx; 2Dx5= fifth 2Dx, etc. International dollars PPP, (UN Data: 
1Arg$ = 1.608 PPP, 2008) were used. Results: Among 45466 discharges ≥ 19 years 
old, we found 1178 discharges with CCS#108 among 1Dx (incidence: 2,59%*; 95%CI 
2,44-2,74%); mortality 0,24% ** (95%CI 0,20-0,29%); 365 days ReH was 60,9% (95%CI 58,1- 
63,7%) and < 30 day ReH of 18,1% (95%CI 15,9- 20,3%). 864 discharges had CCS #108 (HF) 
among any 2Dx (from 1 to 10 2Dx), (incidence: 1,90%; 95%CI 1,77-2,03%) (p< 0,001 vs*), 
descending from 2Dx1: 316, 2Dx5: 89; and 2Dx8: 36 discharges. HF was one among 
several multi-morbid conditions. Outcomes of discharges with 2Dx1 are 365 day ReH: 
57,3 % (95%CI 51,8-62,7%) and < 30 day ReH: 17,1% (95%CI 12,9- 21,2%), mortality 0,09 
(95%CI 0,06-0,12%,(p< 0,001 vs**), case fatality: 12,66% (95%CI 8,99- 16,32%). Mean cost 
per discharge was 7 907 I$ PPP and median cost 1 917 I$PPP for HF in 1Dx; while mean 
was 23316 I$PPP and median cost 12796 I$PPP for CCS #108 in 2Dx5. cOnclusiOns: 
HF is the leading CCS among several criteria of ranking of discharges. Is one of the 
leading causes of admissions as detected by 1Dx. However, HF is frequently sub-
merged as a 2Dx, causes significant mortality, costs and readmissions (ReH). Quality, 
safety and economic studies should consider HF as secondary diagnosis.
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Objectives: Transvenous lead extraction is increasingly required. The aim of this 
study was to determine which factors influence the difficulty of a lead extraction 
procedure through the analysis of a high-volume centre database. MethOds: A 
total of 889 permanent leads were extracted from 469 patients. Factors influencing 
the difficulty of a procedure were assessed using a multivariate logistic regres-
sion model. The fluoroscopy time of the procedure was taken as index of diffi-
culty. Results: From January 2003 to December 2012 , 932 of 946 (98.5%) leads were 
completely removed. Major complications occurred in 1.3% patients. No deaths 
occurred. Median fluoro time was 8.4 min (3.2 - 17.1). A procedure was classified as 
difficult when fluoro time was greater then 31.2 min (90th percentile). At a multivari-
ate analysis the predictors of a difficult procedure were the number of extracted 
leads (OR 1.71, 95%CI 1.06 – 2.8), the presence of screw leads (OR 5.68; 95%CI 1.9 
– 16.9), the presence of dual coil shock leads (OR 5.01, 95%CI 1.27 – 19.8), the years 
since the oldest lead was implanted (OR 1.23, 95%CI 1.15 – 1.31), the absence of leads 
with vegetation (OR 6.76, 95%CI 1.35 – 33.3). The female gender, the patient age at 
extraction, the presence of tachy leads, the presence of lead failure weren’t predic-
ObjectivOs: Identificar el impacto de la obligatoriedad de presentar una 
Evaluación Económica (EE) para la inclusión de medicamentos en el Cuadro Básico 
Nacional en las publicaciones de EE relacionada con el área de reumatología en 
México. MetOdOlOgíAs: Se realizó una búsqueda sistemática de las publi-
caciones de EE y reumatología publicados entre 1995 y 2011. Los estudios de EE 
fueron clasificados por tres expertos en economía de la salud con base a los criterios 
de Drummond, Sí los estudios contemplan comparación de dos o más alterna-
tivas y sí valoran los costos y consecuencias de las alternativas examinadas se 
dice que es un estudio de evaluación económica completa (EEC). Se valoró sí la 
modificación en el año 2003 tuvo impacto significativo en términos de número 
de publicaciones. ResultAdOs: Se identificaron un total de 263 artículos de EE 
entre 1995 y 2011, 93(35%) de fueron EEC. En el periodo 1995-2002 se identificaron 
56 estudios, 19(34%) EEC. En el periodo de 2003-2011 (después de la modificación 
del reglamento) se identificaron un total de 207 publicaciones de EE, 74(36%) EEC. El 
79% de las publicaciones se concentra en el periodo 2003-2011, con un total de 207 
publicaciones. Del total de publicaciones las relacionadas con reumatología fueron 
3% (n= 9) de las cuales 33% fueron completas, 67% fueron parciales. Se destaca que 
antes de la modificación del reglamento en 2003 se detectó un estudio de EE/reuma-
tología mientras que después del año 2003 el número de publicaciones ascendió a 8 
artículos. cOnclusiOnes: La EE en México a través del número de publicaciones se 
ha ido desarrollando notablemente, asimismo el hacer obligatorio el presentar un 
estudio de EE para la inclusión de un insumo al Cuadro Básico y Catálogo de Insumos 
del Sector Salud fue un punto de partida para el desarrollo de la EE en México.
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To inform policy decisions economic evaluation (EE) studies require the system-
atic identification and (quantitative) synthesis of the relevant evidence base on 
the clinical effectiveness, quality of life (QoL) and costs associated with the use of 
competing health technologies. Existing methods for EE are linked to principles of 
evidence-based medicine and, as such, are geared primarily towards the evaluation 
of pharmaceuticals. Some authors have claimed that medical devices (MDs) cannot 
be evaluated using the same principles. We take the opposite viewpoint and argue 
that used within the right evaluative framework existing EE methods are indeed 
appropriate to assess the cost effectiveness of therapeutic MDs. What makes the 
(economic) evaluation of MDs challenging is the fact that the quantity, quality, and 
characteristics of the evidence base around them, is often fragmented, heteroge-
neous and associated with high levels of uncertainty. In these circumstances it is 
important to acknowledge the value of eliciting and quantitatively summarising 
physicians and other experts’ beliefs regarding the effectiveness and resource use 
demands associated with MDs already in use. Using real life examples this paper 
shows how a Bayesian stepwise iterative approach has helped address some of the 
challenges associated with the EE of MDs, while guiding policy decisions regard-
ing technology adoption, research funding and design. Relevant steps include: a) 
identification of existing evidence base and elicitation of experts’ beliefs on clinical 
effectiveness , QoL and costs - i.e. “a priori evidence base”; b) quantitative synthesis 
of this a priori evidence base to inform the parameters of an EE model; (c) initial 
estimation of the model; d) assessment of the economic value of conducting fur-
ther research (VoI); e) collection of new patient level data (PLD) in a pilot study; 
(f) new evaluation of the EE model updating the prior estimates using primary PLD; 
g) further VoI analysis.
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Objectives: To determine the clinical consequences and it’s associated costs of the 
usage of oral anticoagulation therapy for the treatment of atrial fibrillation (AF) in 
Colombia by establishing the cost per disease related event. MethOds: We used a 
6-week cycle length, 17 functional state Markov model of the main clinical outcomes 
in the lifetime of a hypothetical cohort of 1,000 patient with AF per treatment arm. 
The pivotal clinical studies for apixaban, dabigatran, rivaroxaban compared to war-
farin were the source of safety and efficacy data. Data for the analysis was extracted 
from this literature using indirect comparison methods. Costs in Colombian pesos 
2012 are expressed in American dollars (1 US$ = COP$ 1785). To estimate costs, we 
analyzed resource use of a sample of 53 stroke, 148 myocardial infarction, 6 systemic 
embolism patients in San Ignacio University Hospital. Results were validated by an 
expert panel. Results: The number of events associated with each anticoagulant 
therapy (apixaban, dabigatran 110mg, dabigatran 150mg, rivaroxaban and warfarin, 
respectively) were: stroke and systemic embolism 349, 363, 351, 360, 369. ISTH major 
bleedings 235, 212, 233, 280, 277; clinically relevant non major bleedings 342, 337, 357, 
395, 383; myocardial infarctions 102, 114, 116, 101, 104; and event related deaths 459, 
485, 475, 469, 481. Apixaban could be associated with savings in non pharmacological 
cost of $ 360, $170, $145 and $311 per treated patient compared to dabigatran 110mg, 
dabigatran 150mg , rivaroxaban and warfarin, respectively. cOnclusiOns: In this 
